company background image
YMTX logo

Yumanity Therapeutics NasdaqCM:YMTX Stock Report

Last Price

US$13.23

Market Cap

US$143.6m

7D

-8.3%

1Y

-41.3%

Updated

19 Dec, 2022

Data

Company Financials

Yumanity Therapeutics, Inc.

NasdaqCM:YMTX Stock Report

Market Cap: US$143.6m

YMTX Stock Overview

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.

YMTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Yumanity Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Yumanity Therapeutics
Historical stock prices
Current Share PriceUS$13.23
52 Week HighUS$26.45
52 Week LowUS$6.65
Beta0
1 Month Change2.16%
3 Month Change15.24%
1 Year Change-41.30%
3 Year Changen/a
5 Year Changen/a
Change since IPO-91.45%

Recent News & Updates

Recent updates

Shareholder Returns

YMTXUS BiotechsUS Market
7D-8.3%0.2%1.2%
1Y-41.3%7.4%20.5%

Return vs Industry: YMTX underperformed the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: YMTX underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is YMTX's price volatile compared to industry and market?
YMTX volatility
YMTX Average Weekly Movement9.0%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: YMTX has not had significant price volatility in the past 3 months.

Volatility Over Time: YMTX's weekly volatility has decreased from 16% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201441Richard Peterswww.yumanity.com

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein.

Yumanity Therapeutics, Inc. Fundamentals Summary

How do Yumanity Therapeutics's earnings and revenue compare to its market cap?
YMTX fundamental statistics
Market capUS$143.63m
Earnings (TTM)-US$32.00m
Revenue (TTM)US$4.84m

29.7x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
YMTX income statement (TTM)
RevenueUS$4.84m
Cost of RevenueUS$12.45m
Gross Profit-US$7.60m
Other ExpensesUS$24.40m
Earnings-US$32.00m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.95
Gross Margin-156.97%
Net Profit Margin-660.75%
Debt/Equity Ratio0%

How did YMTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.